Trial Profile
An open-label study of the effect of Roferon-A [interferon alpha-2a] plus ribavirin (Copegus) on safety and tolerability in patients with chronic hepatitis C viral infection.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Feb 2010
Price :
$35
*
At a glance
- Drugs Interferon alpha-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors Roche
- 23 Mar 2008 Status changed from in progress to completetd, from Roche record.
- 20 Jun 2006 New trial record.